External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

被引：0
|
作者：
Paganelli, G. [1 ]
Rossetti, C. [2 ]
Aglietta, M. [3 ]
Messina, C. [4 ]
Versari, A. [5 ]
Michalski, J. M. [6 ]
O'Sullivan, J. M. [7 ]
Parker, C. [8 ,9 ]
Garcia-Vargas, J. E. [10 ]
Sartor, A. [11 ]
Finkelstein, S. E. [12 ]
机构：
[1] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, IT, Italy
[2] AO Osped Niguarda Ca Granda, Milan, Italy
[3] IRCCS Candiolo, Candiolo, TO, Italy
[4] AO Papa Giovanni XXIII, Bergamo, IT, Italy
[5] IRCCS AO Arcispedale S Maria Nuova, Reggio Emilia, IT, Italy
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Queens Univ, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
[8] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[9] Inst Canc Res, Sutton, Surrey, England
[10] Bayer HealthCare, Whippany, NJ USA
[11] Tulane Canc Ctr, New Orleans, LA USA
[12] 21st Century Oncol, Scottsdale, AZ USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
F31
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [1] External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial
    Finkelstein, S. E.
    Michalski, J. M.
    O'Sullivan, J.
    Parker, C.
    Garcia-Vargas, J.
    Sartor, O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S201 - S201
  • [2] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.
    Finkelstein, Steven E.
    Michalski, Jeff M.
    O'Sullivan, Joe M.
    Parker, Chris
    Garcia-Vargas, Jose E.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [3] External-beam radiation therapy (EBRT) use and safety with Radium-223 dichloride (Ra) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
    Stroelin, P.
    O'Sullivan, J.
    Sartor, O.
    Parker, C.
    Hoskin, P.
    Widmark, A.
    Mellado, B.
    Helle, S.
    Aksnes, A.
    Garcia-Vargas, J.
    Nilsson, S.
    Oncology Research and Treatment, 2015, 38 : 82 - 82
  • [4] EXTERNAL-BEAM RADIATION THERAPY (EBRT) USE AND SAFETY WITH RADIUM-223 DICHLORIDE (RA) IN PATIENTS (PTS) WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND SYMPTOMATIC BONE METASTASES (METS) FROM THE ALSYMPCATRIAL
    O'Sullivan, J. M.
    Sartor, O.
    Parker, C.
    Hoskin, P.
    Widmark, A.
    Mellado, B.
    Helle, S. I.
    Aksnes, A.
    Garcia-Vargas, J. E.
    Nilsson, S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [5] Radium-223 dichloride (Ra-223) hematologic and 1.5-year posttreatment safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from ALSYMPCA
    Conti, Peter
    Michalski, Jeff
    Skjorestad, Irene
    Wahba, Mona
    Nilsson, Sten
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [6] 3-year safety follow-up of Radium-223 Dichloride (Ra-223) in patients (Pts) with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Kramer, M. W.
    Kuczyk, M. A.
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Coleman, R. E.
    Fang, F.
    Skjorestad, I
    Nilsson, S.
    Oncology Research and Treatment, 2015, 38 : 266 - 266
  • [7] 3-year safety yellow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Parker, Chris
    Vogelzang, Nicholas J.
    Salter, A. Oliver
    Coleman, Robert E.
    Fang, Fang
    Skjorestad, Irene
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [8] Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
    Sun, Y.
    Shi, H.
    Chen, C. -H.
    Lee, J. L.
    Kang, T. W.
    Park, S. H.
    Wu, T. L.
    Ng, Q. S.
    Keam, B.
    Wong, S. C. A.
    Tay, M. H.
    Ding, Q.
    Li, F.
    Ng, D. C. E.
    Liu, X.
    Zhang, Z.
    Guo, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 74
  • [9] 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Amadori, D.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Vogelzang, N. J.
    Sartor, A.
    Coleman, R. E.
    Govi, S.
    Fang, F.
    Skjorestad, I.
    Nilsson, S.
    Parker, C.
    ANNALS OF ONCOLOGY, 2015, 26 : 55 - 55
  • [10] Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases
    Widmark, A.
    Helle, S. I.
    James, N.
    Larsson, A.
    Staudacher, K.
    Haugen, I.
    Garcia-Vargas, J.
    Nilsson, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S189 - S190
12345